Glutaryl-MV3 HD Tablet SR is a combination oral antidiabetic medication containing Glimepiride 3 mg, Metformin 500 mg, and Voglibose 0.2 mg, formulated as a sustained-release tablet. This multi-agent therapy is indicated for the management of type 2 diabetes mellitus in patients inadequately controlled on diet and exercise alone or on monotherapy. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glycemic control without causing significant hypoglycemia. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the intestine, reducing postprandial hyperglycemia. The sustained-release formulation ensures a gradual release of active ingredients, promoting better patient compliance and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Glutaryl-MV3 HD should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular monitoring of blood glucose levels. Caution is advised in patients with renal or hepatic impairment, and it is contraindicated in cases of diabetic ketoacidosis or severe infections. Regular assessment of glycemic control and potential side effects is essential to optimize therapeutic outcomes.